提高发表论文几率的 25 招 诸平 Laura Moss Professor Editor, Canadian Literature phone: 604-822-4226 Laura.Moss@ubc.ca http://blogs.ubc.ca/lauramoss 毕业需要发表论文、评职晋升需要发表论文、申请经费需要发表论文、项目结题也需要发表论文，就在我们为发表论文而犯愁时，《加拿大文学》（ Canadian Literature ）的编辑劳拉•莫斯( Laura Moss )教授，以自己的工作经历，在与作者沟通与交流的过程中，她发现成功发表的文章总是具有某些共同的特征。她2019年5月15日专门撰文—— 25 Ways to Increase Your Chances at Publication ，在文章中为提高论文发表几率给出了25种方法。她在文章中指出，作为一个学术期刊的编辑，经常有人会问到人们如何才能增加他们的文章发表的机会。在过去的五年里，她读了上千份读者报告（审稿意见），写了数百封决议书（投稿回信）。她注意到遗漏和存在的问题。她了解了同龄人读书的目的，以及他们的批评重点往往在哪里。她也知道，大多数学者同时扮演着作者和评价者的双重角色。因此，当她构思自己要为作者支招写这篇提高论文发表几率的25招时，她认为不应该仅仅局限于自己的观察，超越自己的观察可能是有益的。在脸书（Facebook）上，她问过她的同事，在给作者的回信中“你已经给了别人（作者）有用的建议/编辑反馈”吗？他们也提出了自己的看法。因此，下面引用的所有人都在脸书这个社交媒体平台上分享了他们的评论。我感谢所有参与者。有趣的是，几乎所有的评论都是她以前在同行评审报告中看到的。这种众包的建议粗略地说明了，虽然子领域可能有所不同，但读者所看重的可发表学术成果往往具有某些特性。 劳拉·莫斯 博士在加拿大的多伦多大学获学士学位（ University of Toronto, BA ）、在圭尔夫大学获得硕士学位（University of Guelph, MA）、在皇后大学获博士学位（Queen’s University, PhD）。她是英属哥伦比亚大学（ University of British Columbia ， UBC ）的英语教授，教授加拿大文学和非洲文学。劳拉·莫斯自2004年起担任《加拿大文学》杂志副主编，2015年成为《加拿大文学》杂志主编。自2011年以来，她一直是 Canlitguides （ Canadian Literature 的 Twitter ）的特约编辑。 劳拉· 莫斯从 2008年到2011年担任UBC加拿大研究项目和国际加拿大研究中心的主席。从2006年到2010年，她还担任加拿大人文社会科学联合会(CFHSS)学术出版物援助委员会的委员。自2012年春季成立加拿大文艺界女士团体 ( Canadian Women in the Literary Arts ， CWILA )以来， 劳拉·莫斯 一直是 CWILA 的活跃成员。 2012年担任加拿大文艺界女士团体董事会成员(2012-2014年)，2012年担任首届驻场评论家评审团主任（as manager of the jury for the Inaugural Critic-in-Residence in 2012）. In 2013-14, Moss led the UBC GRSJ-CWILA Research Network.）。2013-2014年， 劳拉·莫斯 博士领导了 UBC GRSJ-CWILA研究网络。除了她的五部编辑书籍, 劳拉·莫斯 博士发表了数百篇文章 ,并在文学教育、加拿大公共艺术政策、加拿大广播、以及加拿大温哥华市东（Vancouver’s Downtown Eastside）的公共纪念碑等都有她的贡献。2013年，她被授予UBC基拉姆教学奖（ UBCKillam Teaching Prize for2013 ）。 劳拉·莫斯 博士的建议针对的是各个层次的学者，而不仅仅是刚刚步入科研行列的新手。我们都需要努力寻找最佳的方式来沟通我们的研究。成功的文章都有一些共同的元素，让它们成为阅读和引导阅读过程的乐趣:有力的论据、清晰的组织逻辑和明确的作者观点。她的意见分为三类:1)论文投稿前（有5条建议），2)文章本身（有13条建议），3)收到编辑部评审结果后（有7条建议）。几乎每一点都以她本人在给作者回信中以粗体写的评论开始。她谦虚的称自己的观点没有一个是特别震撼人心的——有些是显而易见的——然而，每一个观点都来自于数十个尚未遵循它的意见书。为了避免误解，还是将 劳拉·莫斯 博士提高论文发表几率的 25 招摘引于下，仅供参考。 1.论文投稿之前（ Before Submission） No.1. Follow submission guidelines. Seriously. Every journal has citation guidelines and word limits. If it says MLA 8, follow MLA 8. Submitting with another style and a note saying, “I’ll change it later if accepted,” signals that you don’t actually see the paper as a good fit in the journal. Similarly, the solution to a paper that is well over the word limit is not to submit it with a note “allowing” the editor to trim it, or saying that you’ll work with the reader’s reports and cut it if it is accepted. The solution is revision before submission. No.2. This paper has too many typos and grammatical errors to go forward to peer review. Submit polished, professional work. University of Alberta professor of English and film studies Julie Rak simply asks us to “write as clearly as you can about complex things.” Let the ideas give weight, not the sentence structure. Do not just assume that copy editors will fix it for you. While finding typos is oddly satisfying, I don’t really relish fixing comma splices. No.3. Peer review is not problem solving. It is a mistake to submit your article because you are stuck and really looking for feedback. This is where you should share drafts with trusted friends or colleagues. It is not the job of the editor or peer reviewers to break your impasse. No.4. Do you know the audience of the journal? A good rule of thumb is to submit to the journals you read and cite most often. You are already participating in their ongoing conversations. You will also know approximately what level of expertise and knowledge your readers might have. My colleague Judith Paltin, assistant professor in the department of English language and literatures at the University of British Columbia, says this: “I’m working on a review right now in which confusion about audience is really evident. The article would neither satisfy specialists, who would be irritated by the extensive foregrounding of seminal scholarship, nor a more heterogeneous audience who still has to wade through a lot of other voices to hear the author’s argument. In short, stop putting other people’s voices ahead of your own as an author.” I absolutely love the final point here. No.5. Sharpen your abstract. Spend time polishing the abstract that you submit with the article. It should summarize the article’s intervention, spell out the core research questions and note the central objects under consideration. The abstract is the article’s first impression. Make it snappy. If you can’t articulate your argument and your contribution to the field clearly in the abstract, you might not have been clear enough in the article, either. 2. 文章本身（ The Article Itself） No.6. How would you assess this article? We ask peer reviewers to consider the following criteria in their assessments of articles for my journal: soundness of scholarship, quality of style, coherence of argument. You should ask yourself about these categories before submitting your paper. Be honest. No.7. Who cares? According to Patricia Badir, professor of English at UBC, you should “let your readers really see how this text or issue interests you: What’s paradoxical? What’s puzzling? What’s surprising?” In the same vein, I can’t stress the significance of “So what?” enough. Life is short. Why should I spend an hour reading this article? I want to know the answer in the opening paragraphs. We all teach students to ask these two fundamental questions. We should keep asking them of our own work. No.8. You need to hook the reader. I often write this statement in decision letters as I send back articles with a request to make the introduction more immediately engaging and to show why it is urgent at the outset. Ask core questions up front. Is it imperative that people read your work? Why now? Epigraphs are your good friends. Take a bit of time in the opening pages to emphasize your contribution to the topic or field. Note that the knowledge gap -- “no one has done this, so I will” -- is never enough. No.9. The logic of organization in this article is unclear. Katja Thieme, instructor in the department of English language and literatures at UBC, points to the value of “establishing a sense of trust in the project that there isn’t just the big bold argument or claim or question that the article asserts, but also and right away, at the beginning, a clear road map.” If written in a way that is not simply a cataloging of what is to come, the map can lead to the wonderful sense of “aha! I see the logic of where we are going. Let’s go!” No.10. Who are you writing for? As Professor Mary Bryson of the department of language and literacy education at UBC notes, “interdisciplinary work by definition needs to imagine and build its own audience.” If you are imagining an audience, imagine out loud. No.11. Who are you in conversation with? While your original article is not a place for an extensive literature review, it is a good place to demonstrate what ongoing conversations you are jumping into or scholarship you are building on. This should be a tight page or three, not half the article. Lorraine York, Distinguished University Professor at McMaster University, looks for “a confident sense of intervention” and notes that “in the most successful articles I read, I feel the excitement at joining that conversation and potentially steering it in a fresh direction. At the same time, that previous conversation shouldn’t overshadow the author’s voice.” Self-confidence doesn't mean posturing or arrogance. It does mean that you believe that you have something significant to add. Also, note that textual interlocutors sometimes come to life. There is a chance that your peer reviewers will come out of your own works cited list. Are you being fair in your articulation of their ideas? No.12. Clarify your citational practices. Here I ask my three favorite questions: Who speaks for whom? Who listens? Who profits? Sandra Tomc, professor of English at UBC, tells us that “the willingness to cite scholarship is probably most important” in her assessment of articles. If research articles are incursions into continuing conversations in the field, whose voices are being heard? As Bryson reminds us, “cite minority voices.” Look at a variety of perspectives -- don’t just cite the usual suspects. No.13. Stop putting other people’s voices ahead of your own, as Paltin says. Avoid name-dropping, particularly theorists. If the work of Jacques Rancière is central to your argument, by all means bring it in. But don’t just cherry-pick a term (“what Rancière calls ‘X’”) without a discussion of where Rancière coined the term, how he uses it and to what end. Is it really worth the necessary space to use the term? If it is, super. Can your voice be heard in the cacophony of theorists? No.14. Reader A is concerned that there is not enough critical engagement with existing scholarship on X. Critical engagement is key here, not just citation. The first thing I do when assessing a new submission is to check the works cited and ask how the author has tracked existing scholarship, how up-to-date (all from 20 years ago?) and historically deep (all from last year?) their references are, how extensive their research is (all online? All from one collection?), and how they have entertained a range of views (counterarguments, existing criticism). Then I read to see how in-depth their interaction with the scholarship is. No.15. Make room for sustained intellectual and analytical engagement with quoted material. It is the author’s job to take the reader through the implications of the passage/case at hand and to relate it to the developing argument. Don’t be afraid to slow down and dig deep into the primary or secondary material. Your original voice will come through here. No.16. Avoid theme spotting. Enough said. No.17. This paper is overly ambitious. Your article is not your dissertation in synopsis or a preview of your upcoming book. Significant contributions to scholarship can be minute and still have impact. As Hannah McGregor, assistant professor in publishing at Simon Fraser University, says, “It is fine to grapple with your subject matter and not solve everything.” Polished does not mean closed down. Further, associate professor of English at UBC Robert Rouse notes that, for him, a great article is one that “moves my understanding along.” Really, that’s what we are trying to do: move understanding along. It can be incremental. That’s how knowledge is mobilized in the long run. No.18. What do you want your reader to remember the most? (Hint: this is likely your contribution to the field.) Conclusions are not just summaries. At the end of an article, you need to make sure that your reader leaves with a takeaway message/point/question. What brief notes would you make if reading your own article? Again, be honest. 3.收到编辑部评审结果后（ After the Report ） No.19. We won’t be moving forward with your article. The majority of articles receive a decision of revise and resubmit (RR) or rejection. You weren’t turned down, your paper was. Try not to take it personally. No.20. Both readers have given you detailed and careful feedback. Contrary to popular belief about the dreaded Reader B, in my experience the vast majority of peer-review reports are sent with the intention of moving scholarship along. I wish more people could see the effort and generous spirit many colleagues put into their reports, reports that are often only viewed by the editor and the writer. Sharing this generosity is actually the best part of being an editor. No.21. You are welcome to request that your article not go back to Reader B upon resubmission. My previous point notwithstanding, not all readers are wonderful. If you don’t think the reader gets your article or is unfair, feel free to request not to send it back to them. No.22. Take the readers’ reports as advice. Reports are advice to the author, not nonnegotiable instructions. Peer readers are well-qualified experts, to be sure, but they have spent hours with the work that you have spent months or years on. Mainly, they are signaling places of confusion, contradiction, omission or points that need clarification or elaboration. Do not completely rewrite according to the recommendations of a single report and in the process lose your own voice. Your name is on the article, not the name of the anonymous reviewer. You have to stand by it. No.23. Let me know what you’ve done. Upon resubmission, if RR, I recommend including a letter to the editor noting the changes you have made, listing the suggestions you have taken up and explaining the ones you have chosen not to engage. No.24. Why didn’t you read the peer reviewers' recommendations? If a reviewer suggests reading something, you must read it. The recommendation signals that they think you are missing a key part of the conversation. You have to listen. If it doesn’t fit, then let the editor know in the revisions explanation letter. More articles get rejected on the second round by the original reader with the comment that “they didn’t even bother to follow up on my recommendations and the holes are still there” than with any other comment. No.25. Onward! Everything we do is a work in progress. If your article is accepted, you still have to work with the editor to polish and tighten it. This will take many hours. If it is RR, then breathe deeply and dig in to the reports. If rejected, read the reports and try to find the valuable suggestions for improvement before submitting elsewhere. Early in my career, I put an article in a drawer after a stinging decision and time passed. It is still not published, and I regret that. If your paper is rejected, take it as a sign that the article is not ready yet, and don’t give up.
(Alice Meadows is Director of Communications for ORCID. Here she talks to Vera Koester for ChemViews Magazine about ORCID iDs, their value for researchers and organizations, and future activities.） http://www.chemistryviews.org/details/ezine/8359901/ORCID__Unique_Author_Identifier.html ORCID 是什么样的组织？ ORCID 是一个开放的、非盈利的、公众推动的组织。它致力于解决学术出版活动中消除作者重名歧义的问题，产生并保存研究者注册的独一无二的身份识别码（ID ），公开透明地把这些识别码跟研究活动及成果相联系。自从ORCID 在2012 年十月发端，已经有超过160 万个身份识别码被登记注册。 为什么ORCID 会成为独一无二的作者标识？ 消除作者重名歧义问题是学术交流中的一个广为人知的问题。很多研究者都有相同或相似的名字，在不同体系和不同作品中，他们的名字可能会被改变或者呈现得不一样。ORCID ID 是唯一的身份标识，被设计成在所有学术平台和系统之间都保持一样。其他的身份标识通常被限制在一个单独的平台、出版商、科研院所（如ResearcherID 和SCOPUS 账号）或是其他更广点儿的平台，但这远远不够。而且，ORCID 是一个选择性加入的系统，研究者或记录持有者的信息是公开还是私密、与什么相连接、谁能编写等问题都是完全可控的。 很多大学，资助方，出版商，以及其他机构组织都推荐或要求他们的研究者使用ORCID ID 。例如，英国惠康基金会（Wellcome Trust ） 已 授 权所有他们认可的申请者使用这个身份识别码 。随着越来越多的人跟着做，ORCID 将会成为学者和科研作家的默认身份标识。 怎样注册ORCID ID 账号？什么样的信息会被保存？ 注册过程又快又方便——大约30 秒就能搞定！要保存的基础数据就是姓名和邮箱地址，虽然我们也推荐研究者添加其他有助于把自己和重名的人区分开来的个人信息。此外可以选择性添加进ORCID 记录的信息有教育经历、工作经验、研究作品（期刊文章、书籍、数据等）、个人网站和社交网络账号，等等。我们不收集出生日期、性别或者电话号码等个人隐私信息。 如何使用ORCID 搜索其他的研究者？ ORCID 的初衷是让研究者和他们的作品在其他平台——本身并非社交平台的地方——可以被人看见。很多研究者把他们的ORCID ID 放在他们的网站和社交网站上，他们被期刊文章和其他出版物提及的几率就越来越高。而且很多研究学者信息系统开始纳入ORCID 身份，使研究者的记录保持在一个最新状态。 还有什么其他的好处？ 正如刚才说到的，ORCID ID 正在被很多其他系统纳入使用。有研究者使用的资助者系统，大学和其他学术机构使用的人力资源、研究信息和其他系统，投稿系统，个人档案系统，等等。ORCID ID 传播得越广，研究者和类似机构获得的价值就越大。 不论工作变动或者姓名改变，研究者都能从多平台使用ORCID 身份识别码这件事中获益匪浅，同时相信他们的隐私是得到保护的。大学和其他研究机构能够更方便地追踪研究者的成果，减少花在更新记录上的时间。资助者可以把研究者及其研究成果相连，再把这些和他们的资助款项相连，从而追踪资金的影响情况。出版商可以提高投稿系统的效率，让更多的人看到作者的作品。学术团体可以把他们的成员在各个系统——会员系统、学术会议和提交稿件、综述评论等等——的活动跨平台连接在一起。最后，ORCID 使日益增强的互操作性和自动更新的信息得以跨越不同研究信息平台同步，报告的时间得以缩短，所以每个人——尤其是研究者——都将从中得到好处。 有人使用ORCID 了吗？ ORCID有超过160 万注册用户，超过300 个会员，145 个动态活跃用户，还有更多的正在发展中。另外还有很多组织机构在使用ORCID公共应用程序编程接口（API ）。近几个月，ORCID与丹麦、意大利和英国及一些其他国家签订了国家财团协议，还有一些交易正在协商，这在不久的未来将会进一步公布。此外，有一些资助方，包括上面提到的最新的英国惠康基金会（UK Wellcome Trust ），已经授权他们认可的申请者使用ORCID ID 。 未来的打算？ 对于ORCID 来说，2015 年是令人兴奋的一年：从 技术上 来说，CrossRef 将很快开始实施自动更新功能。这将允许研究者出版论文时，ORCID 的记录和作者论文的相关信息能够自动更新。接着会做一个相似的数据引用（DataCite ）。 同行评审功能 的第一次动态将很快推出，使组织机构能够往研究者记录里添加关于审查评论的信息。 这些消息和其他的技术更新情况都可以在 公共Trello 工作台 上找到。
ISI Essential Science Indicators（ESI，基本科学指标）是Thomson科技信息集团在汇集和分析ISI Web of Science(SCIE/SSCI)所收录的学术文献及其所引用的参考文献的基础上建立起来的分析型数据库。ESI包括8500多种学术期刊十年来的数据，将所有论文分成22个学科领域。利用ESI,研究人员可以系统地、有针对性地分析国际科技文献,从而了解一些著名的科学家、研究机构（或大学）、国家（或区域）和学术期刊在某一学科领域的发展和影响；同时科研管理人员也可以利用该资源找到影响决策分析的基础数据。利用ESI可以分析十年来国际科学研究的主要领域、研究热点及发展态势。 在《泰晤士报大学排名》中，ESI论文指标的权重占20%；在上海交通大学版的《世界大学学术排名》和《世界大学学科排名》中，论文指标的权重分别占40%和50%。 据统计，在2000年1月1日至2010年12月31日发的中国 高校 发表的SCI论文中，能入ESI高被引论文的也只有不到1%比例，如北京大学（321篇，占1.13%）、清华大学(301篇，0.96%）、浙江大学(150篇，0.50%）、南京大学(109篇，0.57%）、武汉大学(60篇，0.54% ）、东北大学(9篇，0.23%）、西北工业大学(3篇，0.04%）。北浙复清之者，国家自然科学基金一年就能拿下几百项，而十年的ESI高被引论文也最多只有三百余篇。 根据2015年中国大学ESI高被引论文排行榜揭晓(http://gaokao.exam8.com/3225804.html),全国100位高校中山东省内高校情况如下：山东大学84篇，青岛大学29篇，中国海洋大学15篇，中国石油大学14篇，山东理工大学5篇。 根据web of science数据库2015年5月份的最新统计，济南大学共有28篇论文入选ESI高被引论文，位居山东省高校前列。其中化学化工学院17篇，数学科学学院5篇，材料科学与工程学院3篇，物理科学与技术学院1篇，资源与环境学院1篇，经济学院1篇。 《西北工业大学“顶级论文”专项资助计划实施细则》 http://fazhan.nwpu.edu.cn/info/1052/2697.htm ，该校对ESI高被引论文 建设项目 建设经费更是高达50万。 一般大学都没有购买ESI数据库，但你可以利用自己的Research ID 查询ESI全球高引科学家名单。 首先进入你自己的Research ID首页, 然后你可点击右边栏中部 Highly Cited Research ，可查询2015年高引情况。 此数据从10月30日首次公布，接受信息反馈直到12月1日，将于12月中旬公布 最终 结果。 附件是全球材料科学130位ESI高引科学家名单，但不是2015的最终名单。 材料科学ESI高引名单 First Name Last Name Category Primary Affiliation Secondary Affiliation A Paul Alivisatos Materials Science Univ Calif Berkeley, USA Alan J Heeger Materials Science Univ Calif Santa Barbara, USA Alberto Salleo Materials Science Stanford Univ, USA Alex KY Jen Materials Science Univ Washington, USA Zhejiang Univ, China Ali Khademhosseini Materials Science Brigham Womens Hosp, USA King Abdulaziz Univ, Saudi Arabia Andre K Geim Materials Science Univ Manchester, UK Andrea C Ferrari Materials Science Univ Cambridge, UK Antonio Facchetti Materials Science Northwestern Univ, USA Polyera Corp, USA; King Abdulaziz Univ, Saudi Arabia Ben Zhong Tang Materials Science HKUST Shenzhen Res Inst, China Zhejiang Univ, China; Hong Kong Univ Sci Technol, China; SCUT Hong Kong Univ Sci Technol Joint Res Lab, China Bin Liu Materials Science Natl Univ Singapore, Singapore Bruno Scrosati Materials Science Italian Institute of Technology, Italy Catherine J Murphy Materials Science Univ Illinois, USA Chang Ming Li Materials Science Chongqing Key Lab Adv Mat Technol Clean Energie, China Nanyang Technol Univ, Singapore; Southwest Univ, China Charles M Lieber Materials Science Harvard Univ, USA Christoph J Brabec Materials Science Bavarian Ctr Appl Energy Res ZAE Bayern, Germany Univ Erlangen Nurnberg, Germany Chunxia Li Materials Science Chinese Acad Sci, China Clement Sanchez Materials Science UPMC Univ Paris 06, France Dan Li Materials Science Monash Univ, Australia Daniel Moses Materials Science Univ Calif Santa Barbara, USA Daoben Zhu Materials Science Chinese Acad Sci, China David L Kaplan Materials Science Tufts Univ, USA Dmitri Golberg Materials Science Natl Inst Mat Sci, Japan Donal DC Bradley Materials Science Imperial Coll London, UK Dongge Ma Materials Science Chinese Acad Sci, China Dongyuan Zhao Materials Science Fudan Univ, China Evan Ma Materials Science Johns Hopkins Univ, USA Xi An Jiao Tong Univ, China Fengling Zhang Materials Science Linkoping Univ, Sweden Frederik C Krebs Materials Science Tech Univ Denmark, Denmark Fuyou Li Materials Science Fudan Univ, China Gang Li Materials Science Univ Calif Los Angeles, USA Gao Qing (Max) Lu Materials Science Univ Queensland, Australia Guillermo C Bazan Materials Science Univ Calif Santa Barbara, USA King Abdulaziz Univ, Saudi Arabia Guozhong Cao Materials Science Univ Washington, USA Henning Sirringhaus Materials Science Univ Cambridge, UK Hin-Lap Yip Materials Science S China Univ Technol, China Hongbin Wu Materials Science S China Univ Technol, China Hongjie Dai Materials Science Stanford Univ, USA Hua Zhang Materials Science Nanyang Technol Univ, Singapore Hui-Ming Cheng Materials Science Chinese Acad Sci, China King Abdulaziz Univ, Saudi Arabia Iain McCulloch Materials Science King Abdullah Univ Sci Technol, Saudi Arabia Imperial Coll London, UK James R Durrant Materials Science Imperial Coll London, UK Swansea Univ, UK Jan C Hummelen Materials Science Univ Groningen, Netherlands Jean MJ Frechet Materials Science King Abdullah Univ Sci Technol, Saudi Arabia Univ Calif Berkeley, USA Jean-Marie Tarascon Materials Science Coll France, France Jenny Nelson Materials Science Imperial Coll London, UK Jiaguo Yu Materials Science Wuhan Univ Technol, China King Abdulaziz Univ, Saudi Arabia Jianhui Hou Materials Science Chinese Acad Sci, China Jianlin Shi Materials Science Chinese Acad Sci, China Jim Yang Lee Materials Science Natl Univ Singapore, Singapore Jinghong Li Materials Science Tsinghua Univ, China Joachim Maier Materials Science Max Planck Inst Solid State Res, Germany John A Rogers Materials Science Univ Illinois, USA Jonathan N Coleman Materials Science Trinity Coll Dublin, Ireland Jun Lin Materials Science Chinese Acad Sci, China Jun Liu Materials Science Pacific NW Natl Lab, USA Jun Song Chen Materials Science Nanyang Technol Univ, Singapore Junji Kido Materials Science Yamagata Univ, Japan Karl Leo Materials Science Tech Univ Dresden, Germany Katsuhiko Ariga Materials Science Natl Inst Mat Sci, Japan Ke Lu Materials Science Chinese Acad Sci, China Klaus Muellen Materials Science Max Planck Inst Polymer Res, Germany Konstantin S Novoselov Materials Science Univ Manchester, UK Lei Lu Materials Science Chinese Acad Sci, China Lei Jiang Materials Science Chinese Acad Sci, China Li-Jun Wan Materials Science Chinese Acad Sci, China Linjie Zhi Materials Science Natl Ctr Nanosci Technol China, China Lixiang Wang Materials Science Chinese Acad Sci, China Luis M Liz-Marzan Materials Science CIC biomaGUNE, Spain Basque Fdn Sci, Spain Lynden A Archer Materials Science Cornell Univ, USA Maggie Paulose Materials Science Univ Houston, USA Markus Antonietti Materials Science Max Planck Inst Colloids Interfaces, Germany Martijn M Wienk Materials Science Eindhoven Univ Technol, Netherlands Martin Heeney Materials Science Imperial Coll London, UK Michael Graetzel Materials Science Ecole Polytech Fed Lausanne, Switzerland Sungkyunkwan Univ, South Korea Michael D McGehee Materials Science Stanford Univ, USA Michael F Toney Materials Science SLAC Natl Accelerator Lab, USA Michael S Strano Materials Science MIT, USA Mikkel Jorgensen Materials Science Tech Univ Denmark, Denmark Miqin Zhang Materials Science Univ Washington, USA Mohammad Khaja Nazeeruddin Materials Science Ecole Polytech Fed Lausanne, Switzerland King Abdulaziz Univ, Saudi Arabia Nicola A Spaldin Materials Science ETH Zurich, Switzerland Niyazi Serdar Sariciftci Materials Science Johannes Kepler Univ Linz, Austria Olle Inganas Materials Science Linkoping Univ, Sweden Oomman K Varghese Materials Science Univ Houston, USA Paul WM Blom Materials Science Max Planck Inst Polymer Res, Germany Peidong Yang Materials Science Univ Calif Berkeley, USA Pulickel M Ajayan Materials Science Rice Univ, USA Rainer Waser Materials Science Res Ctr Julich GmbH, Germany Rhein Westfal TH Aachen, Germany Ramamoorthy Ramesh Materials Science Univ Calif Berkeley, USA Rene AJ Janssen Materials Science Eindhoven Univ Technol, Netherlands Richard H Friend Materials Science Univ Cambridge, UK Robert Langer Materials Science MIT, USA Rodney S Ruoff Materials Science Ulsan Natl Inst Sci Tech, South Korea Samson A Jenekhe Materials Science Univ Washington, USA Seeram Ramakrishna Materials Science Natl Univ Singapore, Singapore Shaik M Zakeeruddin Materials Science Ecole Polytech Fed Lausanne, Switzerland King Abdulaziz Univ, Saudi Arabia Shu-Hong Yu Materials Science Univ Sci Technol China, China King Abdulaziz Univ, Saudi Arabia Shuit-Tong Lee Materials Science Soochow Univ, China Stephen R Forrest Materials Science Univ Michigan, USA Subra Suresh Materials Science Carnegie Mellon Univ, USA Taeghwan Hyeon Materials Science Seoul Natl Univ, South Korea Thomas P Russell Materials Science Univ Mass System, USA Thuc-Quyen Nguyen Materials Science Univ Calif Santa Barbara, USA Tianyou Zhai Materials Science School of Materials Science and Engineering, China Tobin J Marks Materials Science Northwestern Univ, USA Ulrich S Schubert Materials Science Univ Jena, Germany Wai-Yeung Wong Materials Science Hong Kong Baptist Univ, China Univ Grants Comm, China Wolfgang J Parak Materials Science Philipps Univ Marburg, Germany CIC biomaGUNE, Spain Xiaosheng Fang Materials Science Fudan Univ, China King Abdulaziz Univ, Saudi Arabia Xinliang Feng Materials Science Max Planck Inst Polymer Res, Germany Xiong Gong Materials Science Coll of Polymer Science and Polymer Engineering, USA Xiong Wen (David) Lou Materials Science Nanyang Technol Univ, Singapore Yadong Li Materials Science Tsinghua Univ, China Yang Yang Materials Science Univ Calif Los Angeles, USA Yi Cui Materials Science Stanford Univ, USA Yong Cao Materials Science S China Univ Technol, China Yong-Sheng Hu Materials Science Chinese Acad Sci, China Yongfang Li Materials Science Chinese Acad Sci, China Soochow Univ, China Yonggang Y Huang Materials Science Northwestern Univ, USA Yongsheng Chen Materials Science Nankai Univ, China Yoshio Bando Materials Science Natl Inst Mat Sci, Japan Younan Xia Materials Science Georgia Inst Technol, USA Yu-Guo Guo Materials Science Chinese Acad Sci, China Yugang Sun Materials Science Argonne Natl Lab, USA Yunqi Liu Materials Science Chinese Acad Sci, China Yury Gogotsi Materials Science Drexel Univ, USA Zhenan Bao Materials Science Stanford Univ, USA Zhong Lin Wang Materials Science Georgia Inst Technol, USA Zhuang Liu Materials Science Soochow Univ, China Zongyou Yin Materials Science Nanyang Technol Univ, Singapore
最近一期《Science》上发表了一篇有关今年爆发的埃博拉病毒基因组测序论文，从其分析结果中推断了关于此次疫情的来源和传播模式： Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak。 这无疑是一篇极为 重要的文章，这篇貌似与平常论文一样的文章却有着非同寻常的沉重故事。 这篇国际合作 论文有 58名共同作者，文章8月5号投稿，21号接受。 《Science》同时报道了 令人遗憾的消息：有六位共同作者没能看到论文的发表，其中，五名作者是在工作中因直接感染了埃博拉病毒而牺牲，一名是在文章后期因中风去世。 Ebola's heavy toll on study authors 。 我试图从下面作者名单群中找到这六位作者名字，还颇费了点时间。国际合作论文的作者众多，他们的名字太容易被忽略了。以黑框标出的去世作者有：Mbalu Fonnie，Alex Moigboi，Alice Kovoma，Mohamed Fullah，Sheik Humarr Khan 和 Sidiki Saffa。让人震惊和难过的是，他们名字后面有个共同点，都 注明 了 个“3”，即隶属于塞拉里昂凯内马政府医院（Kenema Government Hospital, Kenema, Sierra Leone－KGH），他们 是工作在抗埃博拉第一线医护人员和科技人员。 从“Supplementary Materials ”可以清楚了解到KGH的科研人员如何工作的。他们遵循严格的工作程序筛选可疑病例，准确记录并收集血液样品，分离血浆或者血清，原地提取病毒RNA并诊断 埃博拉病人 ，最后所有生物样品按严格要求冷冻空运送到美国哈佛大学供进一步分析研究。令人赞赏和敬佩的是，KGH本土科学家所做的PCR分析结果质量之高，与后来在美国哈佛进行重复检验结果完全一致，这里有一句简单描述话可以说明 凯内马 科学家是如何完成好他们的 工作的： “ All samples testing positive at the field site were found to be positive by qRT-PCR and sequencing at Harvard. Additionally, all samples testing negative for EBOV at the field also tested negative at Harvard.” 可 以想像，没有他们的认真，努力和牺牲，远在美国和英国的那些顶尖科学家们是无法得到可靠的病人血液样品，无法对埃博拉病毒的来龙去脉进行探索， 也就没有这篇重要论文了 。 这篇用一线工作者生命换来的文章读起来很沉重，科研有时要牺牲，但愿他们的牺牲能为人类早点战胜埃博拉病毒做出贡献。 借此谨向工作在抗埃博拉一线医护人员和科学家表示由衷敬意。 Ebola's heavy toll on study authors
Several days ago I discussed the authorship, and today I retrieved one superpaperentitled " Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs "---a reviewarticlewithmore than 200individualauthorsfrom 269 institutions and one corporate author, and supported by 108 funding organizations.This paper waspublished in 2012 on JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (impact factor of this journal is 11.003) Whether it can be called the "superman" in thepaper publication field? I am sure it will be cited by manymany times because it has so manyauthors.If we assumeeach of theauthorshas afans team, the fans of this paper will be in thousands. I am a little curiousabout how the authors are organized. Didthey meet in an international conference and then start to discuss the creation of this super paper?Orwas it initiated by a prestigiousperson (maybe the first author)and then start this super project? Any way, the scene is very splendid with so many people and organizations scraped together! The follows is the related information of this article. _________________________ 标题 Title: Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs 作者 Author: Bousquet, J (Bousquet, J.) 1 , 2 ; Schunemann, HJ (Schuenemann, H. J.) 3 ; Samolinski, B (Samolinski, B.) 4 ; Demoly, P (Demoly, P.) 1 , 5 ; Baena-Cagnani, CE (Baena-Cagnani, C. E.) 6 , 7 ; Bachert, C (Bachert, C.) 8 ; Bonini, S (Bonini, S.) 9 , 10 ; Boulet, LP (Boulet, L. P.) 11 ; Bousquet, PJ (Bousquet, P. J.) 1 ; Brozek, JL (Brozek, J. L.) 3 ; Canonica, GW (Canonica, G. W.) 12 ; Casale, TB (Casale, T. B.) 13 ; Cruz, AA (Cruz, A. A.) 14 , 15 ; Fokkens, WJ (Fokkens, W. J.) 16 , 17 ; Fonseca, JA (Fonseca, J. A.) 18 , 19 , 20 , 21 ; van Wijk, RG (van Wijk, R. Gerth) 22 ; Grouse, L (Grouse, L.) 23 ; Haahtela, T (Haahtela, T.) 24 ; Khaltaev, N (Khaltaev, N.) 25 ; Kuna, P (Kuna, P.) 26 ; Lockey, RF (Lockey, R. F.) 27 , 28 ; Carlsen, KCL (Carlsen, K. C. Lodrup) 29 ; Mullol, J (Mullol, J.) 30 , 31 ; Naclerio, R (Naclerio, R.) 32 ; O'Hehir, RE (O'Hehir, R. E.) 33 , 34 ; Ohta, K (Ohta, K.) 35 ; Palkonen, S (Palkonen, S.) 36 ; Papadopoulos, NG (Papadopoulos, N. G.) 37 ; Passalacqua, G (Passalacqua, G.) 12 ; Pawankar, R (Pawankar, R.) 38 ; Price, D (Price, D.) 39 ; Ryan, D (Ryan, D.) 40 , 41 ; Simons, FER (Simons, F. E. R.) 42 ; Togias, A (Togias, A.) 43 ; Williams, D (Williams, D.) 44 ; Yorgancioglu, A (Yorgancioglu, A.) 45 ; Yusuf, OM (Yusuf, O. M.) 46 ; Aberer, W (Aberer, W.) 47 ; Adachi, M (Adachi, M.) 48 ; Agache, I (Agache, I.) 49 ; Ait-Khaled, N (Ait-Khaled, N.) 50 ; Akdis, CA (Akdis, C. A.) 51 ; Andrianarisoa, A (Andrianarisoa, A.) 52 ; Annesi-Maesano, I (Annesi-Maesano, I.) 53 , 54 ; Ansotegui, IJ (Ansotegui, I. J.) 55 ; Baiardini, I (Baiardini, I.) 12 ; Bateman, ED (Bateman, E. D.) 56 ; Bedbrook, A (Bedbrook, A.) 57 ; Beghe, B (Beghe, B.) 58 ; Beji, M (Beji, M.) 59 ; Bel, EH (Bel, E. H.) 60 ; Ben Kheder, A (Ben Kheder, A.) 61 ; Bennoor, KS (Bennoor, K. S.) 62 , 63 ; Bergmann, KC (Bergmann, K. C.) 64 ; Berrissoul, F (Berrissoul, F.) ; Bieber, T (Bieber, T.) 65 ; Jensen, CB (Jensen, C. Bindslev) 66 , 67 ; Blaiss, MS (Blaiss, M. S.) 68 ; Boner, AL (Boner, A. L.) 69 ; Bouchard, J (Bouchard, J.) 70 , 71 ; Braido, F (Braido, F.) 12 ; Brightling, CE (Brightling, C. E.) 72 ; Bush, A (Bush, A.) 73 ; Caballero, F (Caballero, F.) 75 ; Calderon, MA (Calderon, M. A.) 74 ; Calvo, MA (Calvo, M. A.) 76 ; Camargos, PAM (Camargos, P. A. M.) 77 ; Caraballo, LR (Caraballo, L. R.) 78 ; Carlsen, KH (Carlsen, K. H.) 29 ; Carr, W (Carr, W.) 79 ; Cepeda, AM (Cepeda, A. M.) 80 ; Cesario, A (Cesario, A.) 81 , 82 ; Chavannes, NH (Chavannes, N. H.) 83 ; Chen, YZ (Chen, Y. Z.) 84 , 85 , 86 ; Chiriac, AM (Chiriac, A. M.) 87 ; Perez, TC (Chivato Perez, T.) 88 ; Chkhartishvili, E (Chkhartishvili, E.) 89 ; Ciprandi, G (Ciprandi, G.) 90 ; Costa, DJ (Costa, D. J.) 91 ; Cox, L (Cox, L.) 92 ; Custovic, A (Custovic, A.) 93 ; Dahl, R (Dahl, R.) 94 ; Darsow, U (Darsow, U.) 95 , 96 , 97 ; De Blay, F (De Blay, F.) 98 ; Deleanu, D (Deleanu, D.) 99 ; Denburg, JA (Denburg, J. A.) 100 , 101 ; Devillier, P (Devillier, P.) 102 ; Didi, T (Didi, T.) 103 ; Dokic, D (Dokic, D.) 104 ; Dolen, WK (Dolen, W. K.) 105 ; Douagui, H (Douagui, H.) 106 ; Dubakiene, R (Dubakiene, R.) 107 ; Durham, SR (Durham, S. R.) 108 ; Dykewicz, MS (Dykewicz, M. S.) 109 ; El-Gamal, Y (El-Gamal, Y.) 110 , 111 ; El-Meziane, A (El-Meziane, A.) 112 , 113 ; Emuzyte, R (Emuzyte, R.) 114 ; Fiocchi, A (Fiocchi, A.) 115 ; Fletcher, M (Fletcher, M.) 116 ; Fukuda, T (Fukuda, T.) 117 ; Gamkrelidze, A (Gamkrelidze, A.) 118 ; Gereda, JE (Gereda, J. E.) 119 ; Diaz, SG (Gonzalez Diaz, S.) 120 ; Gotua, M (Gotua, M.) 121 ; Guzman, MA (Guzman, M. A.) 122 ; Hellings, PW (Hellings, P. W.) 123 ; Hellquist-Dahl, B (Hellquist-Dahl, B.) 124 ; Horak, F (Horak, F.) 125 ; Hourihane, JO (Hourihane, J. O'B.) 126 ; Howarth, P (Howarth, P.) 127 ; Humbert, M (Humbert, M.) 128 ; Ivancevich, JC (Ivancevich, J. C.) 129 ; Jackson, C (Jackson, C.) 130 ; Just, J (Just, J.) 131 ; Kalayci, O (Kalayci, O.) 132 ; Kaliner, MA (Kaliner, M. A.) 133 , 134 ; Kalyoncu, AF (Kalyoncu, A. F.) 135 ; Keil, T (Keil, T.) 136 ; Keith, PK (Keith, P. K.) 137 ; Khayat, G (Khayat, G.) 138 , 139 ; Kim, YY (Kim, Y. Y.) 140 , 141 , 142 ; N'Goran, BK (N'Goran, B. Koffi) 143 ; Koppelman, GH (Koppelman, G. H.) 144 ; Kowalski, ML (Kowalski, M. L.) 145 ; Kull, I (Kull, I.) 146 , 147 ; Kvedariene, V (Kvedariene, V.) 148 , 149 ; Larenas-Linnemann, D (Larenas-Linnemann, D.) 150 ; Le, LT (Le, L. T.) 151 ; Lemiere, C (Lemiere, C.) 152 , 153 ; Li, J (Li, J.) 154 ; Lieberman, P (Lieberman, P.) 155 ; Lipworth, B (Lipworth, B.) 156 ; Mahboub, B (Mahboub, B.) 157 , 158 ; Makela, MJ (Makela, M. J.) 159 ; Martin, F (Martin, F.) ; Marshall, GD (Marshall, G. D.) 160 ; Martinez, FD (Martinez, F. D.) 161 , 162 ; Masjedi, MR (Masjedi, M. R.) 163 , 164 ; Maurer, M (Maurer, M.) 165 ; Mavale-Manuel, S (Mavale-Manuel, S.) 166 , 167 ; Mazon, A (Mazon, A.) 168 ; Melen, E (Melen, E.) 169 , 170 ; Meltzer, EO (Meltzer, E. O.) 171 , 172 ; Mendez, NH (Mendez, N. H.) 173 ; Merk, H (Merk, H.) 174 ; Mihaltan, F (Mihaltan, F.) 175 ; Mohammad, Y (Mohammad, Y.) 176 ; Morais-Almeida, M (Morais-Almeida, M.) 177 ; Muraro, A (Muraro, A.) 178 ; Nafti, S (Nafti, S.) 179 ; Namazova-Baranova, L (Namazova-Baranova, L.) 180 ; Nekam, K (Nekam, K.) 181 ; Neou, A (Neou, A.) 182 ; Niggemann, B (Niggemann, B.) 183 ; Nizankowska-Mogilnicka, E (Nizankowska-Mogilnicka, E.) 184 ; Nyembue, TD (Nyembue, T. D.) 185 ; Okamoto, Y (Okamoto, Y.) 186 ; Okubo, K (Okubo, K.) 187 ; Orru, MP (Orru, M. P.) ; Ouedraogo, S (Ouedraogo, S.) 188 ; Ozdemir, C (Ozdemir, C.) 189 , 190 ; Panzner, P (Panzner, P.) 191 ; Pali-Scholl, I (Pali-Schoell, I.) 192 , 193 , 194 ; Park, HS (Park, H. S.) 195 ; Pigearias, B (Pigearias, B.) 196 , 197 ; Pohl, W (Pohl, W.) 198 ; Popov, TA (Popov, T. A.) 199 ; Postma, DS (Postma, D. S.) 200 ; Potter, P (Potter, P.) 201 , 202 ; Rabe, KF (Rabe, K. F.) 203 , 204 ; Ratomaharo, J (Ratomaharo, J.) 205 ; Reitamo, S (Reitamo, S.) 206 ; Ring, J (Ring, J.) 207 ; Roberts, R (Roberts, R.) 208 ; Rogala, B (Rogala, B.) 209 ; Romano, A (Romano, A.) 210 , 211 ; Rodriguez, MR (Rodriguez, M. Roman) 212 ; Rosado-Pinto, J (Rosado-Pinto, J.) 213 ; Rosenwasser, L (Rosenwasser, L.) 214 , 215 ; Rottem, M (Rottem, M.) 216 , 217 ; Sanchez-Borges, M (Sanchez-Borges, M.) 218 ; Scadding, GK (Scadding, G. K.) 219 ; Schmid-Grendelmeier, P (Schmid-Grendelmeier, P.) 220 ; Sheikh, A (Sheikh, A.) 221 ; Sisul, JC (Sisul, J. C.) ; Sole, D (Sole, D.) 222 ; Sooronbaev, T (Sooronbaev, T.) 223 ; Spicak, V (Spicak, V.) 224 ; Spranger, O (Spranger, O.) 225 ; Stein, RT (Stein, R. T.) 226 , 227 ; Stoloff, SW (Stoloff, S. W.) 228 ; Sunyer, J (Sunyer, J.) 226 , 229 , 230 , 231 ; Szczeklik, A (Szczeklik, A.) 232 ; Todo-Bom, A (Todo-Bom, A.) 233 ; Toskala, E (Toskala, E.) 234 , 235 ; Tremblay, Y (Tremblay, Y.) 236 ; Valenta, R (Valenta, R.) 237 ; Valero, AL (Valero, A. L.) 238 , 239 , 240 ; Valeyre, D (Valeyre, D.) 241 , 242 ; Valiulis, A (Valiulis, A.) 243 , 244 ; Valovirta, E (Valovirta, E.) 245 , 246 ; Van Cauwenberge, P (Van Cauwenberge, P.) 247 ; Vandenplas, O (Vandenplas, O.) 248 ; van Weel, C (van weel, C.) 249 ; Vichyanond, P (Vichyanond, P.) 250 ; Viegi, G (Viegi, G.) 251 , 252 ; Wang, DY (Wang, D. Y.) 253 ; Wickman, M (Wickman, M.) 254 , 255 ; Wohrl, S (Woehrl, S.) 256 , 257 ; Wright, J (Wright, J.) 258 ; Yawn, BP (Yawn, B. P.) 259 , 260 ; Yiallouros, PK (Yiallouros, P. K.) 261 , 262 ; Zar, HJ (Zar, H. J.) 263 ; Zernotti, ME (Zernotti, M. E.) 264 ; Zhong, N (Zhong, N.) 265 ; Zidarn, M (Zidarn, M.) 267 ; Zuberbier, T (Zuberbier, T.) 268 , 269 团体作者: World Hlth Org Collaborating Ctr 来源出版物: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 卷: 130 期: 5 页: 1049-1062 DOI: 10.1016/j.jaci.2012.07.053 出版年: NOV 2012 摘要: Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.) 机构(地址): 1. Hop Arnaud Villeneuve, Dept Resp Dis, Univ Hosp, Montpellier, France 2. INSERM, U1018, CESP Ctr Res Epidemiol Populat Hlth, Resp Environm Epidemiol Team, Villejuif, France 3. McMaster Univ, Dept Clin Epidemiol Biostat Med, Hamilton, ON, Canada 4. Med Univ Warsaw, Dept Prevent Environm Hazards Allergol, Warsaw, Poland 5. Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U657, Montpellier, France 6. Catholic Univ, Fac Med, Res Ctr Resp Med CIMER, Cordoba, Argentina 7. Univ Genoa, Sch Specializat, Genoa, Italy 8. Univ Ghent, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium 9. CNR, Inst Translat Pharmacol, Rome, Italy 10. Univ Naples 2, Naples, Italy 11. Univ Laval, Inst Univ Cardiol Pneumol Quebec, Quebec City, PQ, Canada 12. Univ Genoa, Dept Internal Med, DIMI, I-16126 Genoa, Italy 13. Creighton Univ, Dept Med, Div Allergy Immunol, Omaha, NE 68178 USA 14. Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil 15. CNPq, Salvador, BA, Brazil 16. Univ Amsterdam, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands 17. Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands 18. Univ Porto, Sch Med, Dept Hlth Informat Decis Sci, P-4100 Oporto, Portugal 19. Univ Porto, Sch Med, CINTESIS, P-4100 Oporto, Portugal 20. Hosp S Joao Inst, Dept Allergy, Oporto, Portugal 21. Hosp CUF Porto, Oporto, Portugal 22. Erasmus MC, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands 23. Univ Washington, Sch Med, Seattle, WA USA 24. Helsinki Univ Hosp, Dept Allergy, Skin Allergy Hosp, Helsinki, Finland 25. GARD ARIA Coordinator, Geneva, Switzerland 26. Med Univ Lodz, Dept Internal Med Asthma Allergy, Barlicki Univ Hosp, Lodz, Poland 27. Univ S Florida, Coll Med, Dept Internal Med, Div Allergy Immunol, Tampa, FL 33612 USA 28. James A Haley Vet Hosp, Tampa, FL USA 29. Univ Oslo, Oslo Univ Hosp, Dept Paediat, Oslo, Norway 30. CIBERES, IDIBAPS, Hosp Clin, Rhinol Unit,ENT Dept, Barcelona, Spain 31. CIBERES, IDIBAPS, Hosp Clin, Smell Clin,ENT Dept, Barcelona, Spain 32. Univ Chicago, Dept Otolaryngol Head Neck Surg, Chicago, IL 60637 USA 33. Alfred Hosp, Dept Allergy Immunol Resp Med, Melbourne, Vic, Australia 34. Monash Univ, Melbourne, Vic 3004, Australia 35. Teikyo Univ, Sch Med, Dept Med, Div Resp Med Allergol, Tokyo 173, Japan 36. EFA European Federat Allergy Airways Dis Patien, Brussels, Belgium 37. Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece 38. Nippon Med Sch, Bunkyo Ku, Tokyo 113, Japan 39. Univ Aberdeen, Dept Primary Care Resp Med, Aberdeen, Scotland 40. Woodbrook Med Ctr, Loughborough, Leics, England 41. Univ Edinburgh, Edinburgh, Midlothian, Scotland 42. Univ Manitoba, Fac Med, Winnipeg, MB, Canada 43. NIAID, Bethesda, MD 20892 USA 44. Univ N Carolina, Sch Pharm, Chapel Hill, NC USA 45. Celal Bayar Univ, Sch Med, Dept Pulmonol, Manisa, Turkey 46. Allergy Asthma Inst, Islamabad, Pakistan 47. Med Univ Graz, Dept Dermatol, Graz, Austria 48. Showa Univ, Sch Med, Div Allergol Resp Med, Tokyo 142, Japan 49. Transylvania Univ, Fac Med, Brasov, Romania 50. Int Union TB Lung Dis Union, Paris, France 51. Univ Zurich, Swiss Inst Allergy Asthma Res SIAF, Davos, Switzerland 52. Minist Hlth, Publ Hosp Med Serv, Antananarivo, Madagascar 53. INSERM, EPAR U707, Paris, France 54. Univ Paris 06, EPAR, UMR S, Paris, France 55. Hosp Quiron Bizkaia, Dept Allergy Immunol, Erandio Bilbao, Spain 56. Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa 57. WHO, Collaborating Ctr Asthma Rhinitis, Montpellier, France 58. Univ Modena Reggio Emilia, Dept Oncol Hematol Resp Dis, Modena, Italy 59. Ctr Hosp Univ Rabta, Serv Pneumol Allergol, Tunis, Tunisia 60. Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands 61. Hop Mami, Ariana, Tunisia 62. Bangladesh Lung Fdn, Dhaka, Bangladesh 63. Natl Inst Dis Chest Hosp, Dhaka, Bangladesh 64. Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany 65. Univ Med Ctr, Dept Dermatol Allergy, Bonn, Germany 66. Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark 67. Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark 68. Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA 69. Univ Verona, Dept Paediat, I-37100 Verona, Italy 70. Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada 71. Hop Malbaie, La Malbaie, PQ, Canada 72. Univ Leicester, Inst Lung Hlth, Leicester LE1 7RH, Leics, England 73. Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England 74. Univ London Imperial Coll Sci Technol Med, Natl Heart Lung Inst, Sect Allergy Clin Immunol, London, England 75. Ctr Med Docente La Trinidad Caracas, Dept Immunol, Caracas, Venezuela 76. Univ Austral Chile, Fac Med, Dept Pediat, Valdivia, Chile 77. Univ Fed Sao Joao del Rei, Hlth Sci Ctr, Hlth Sci Postgrad Program, Divinopolis, Brazil 78. Univ Cartagena, Immunol Res Inst, Cartagena De Indias, Colombia 79. So Calif Res, Mission Viejo, CA USA 80. Metropolitan Univ Barranquilla, Allergy Immunol Lab, Barranquilla, Colombia 81. IRCCS San Raffaele Pisana, Rome, Italy 82. Univ Cattolica Sacro Cuore, Dept Thorac Surg, Rome, Italy 83. Leiden Univ, Med Ctr, Dept Publ Hlth Primary Care, Leiden, Netherlands 84. Capital Inst Pediat, Asthma Clin, Natl Cooperat Grp Pediat Res Asthma, Beijing, Peoples R China 85. Capital Inst Pediat, Educ Ctr, Beijing, Peoples R China 86. Ctr Asthma Res Educ, Beijing, Peoples R China 87. Hop Arnaud Villeneuve, Univ Hosp, Allergy Unit, Montpellier, France 88. Univ Hosp, Dept Allergol, Sch Med CEU San Pablo Madrid, Madrid, Spain 89. Georgian Natl Univ, AIETI Med Sch, SEU Clin, Med Ctr, Tbilisi, Rep of Georgia 90. Univ Genoa, Dept Internal Med, IRCCS Azienda Osped Univ San Martino, I-16126 Genoa, Italy 91. Univ Montpellier I, Primary Care Dept, Montpellier, France 92. Nova SE Univ, Coll Osteopath Med, Davie, FL USA 93. Univ Manchester, Manchester, Lancs, England 94. Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark 95. Tech Univ Munich, Dept Dermatol Allergy Biederstein, Munich, Germany 96. TUM, Div Environm Dermatol, Munich, Germany 97. TUM, Allergy Helmholtz Ctr, Munich, Germany 98. Univ Hosp Strasbourg, Chest Dis Dept, Div Pulmonol Asthma Allergol, Strasbourg, France 99. Univ Med Pharm Iuliu Hatieganu, Dept Allergy, Med Clin 3, Romanian Soc Allergy Clin Immunol, Cluj Napoca, Romania 100. McMaster Univ, AllerGen NCE, Dept Med, Hamilton, ON, Canada 101. McMaster Univ, AllerGen NCE, Michael G DeGroote Sch Med, Div Clin Immunol Allergy,Fac Hlth Sci, Hamilton, ON, Canada 102. Univ Versailles St Quentin, Hop Foch, UPRES EA 220, Suresnes, France 103. Ctr Hosp Reg Annecy, Serv Pneumol, Annecy, France 104. Univ Ss Cyril Methodius, Univ Clin Pulmonol Allergy, Skopje, Macedonia 105. Georgia Hlth Sci Univ, Augusta, GA USA 106. Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria 107. Vilnius Univ, Fac Med, Collaborating Ctr GA2LEN, Vilnius, Lithuania 108. Univ London Imperial Coll Sci Technol Med, Natl Heart Lung Inst, London, England 109. Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA 110. Ain Shams Univ, Childrens Hosp, Pediat Allergy Immunol Unit, Cairo, Egypt 111. Egyptian Soc Pediat Allergy Immunol, Cairo, Egypt 112. Soc Marocaine Malad Resp, Casablanca, Morocco 113. Ctr Resp Dis Allergy, Casablanca, Morocco 114. Vilnius Univ, Fac Med, Vilnius, Lithuania 115. Univ Milan, Sch Med, Melloni Hosp, Milan, Italy 116. Educ Hlth, Warwick, England 117. Dokkyo Med Univ, Mibu, Tochigi, Japan 118. WHO, Country Off Georgia, Tbilisi, Rep of Georgia 119. Clin Ricardo Palma, Lima, Peru 120. Univ Nuevo Leon UANL, Hosp Univ, Fac Med, Monterrey, Mexico 121. Ctr Allergy Immunol, Tbilisi, Rep of Georgia 122. Clin Hosp Univ Chile, Dept Med, Immunol Allergol Div, Santiago, Chile 123. Univ Hosp Leuven, Dept Otorhinolaryngol Head Neck Surg, Louvain, Belgium 124. Cent Reg Denmark, Ctr Publ Hlth Qual Improvement, Aarhus, Denmark 125. Allergy Ctr Vienna W, Vienna, Austria 126. Natl Univ Ireland Univ Coll Cork, Dept Paediat Child Hlth, Cork, Ireland 127. Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England 128. Univ Paris 11, Serv Pneumol, Hop Antoine Beclere, AP HP,INSERM,U999, Clamart, France 129. Salvador Univ, Sch Med, Dept Immunol, Buenos Aires, DF, Argentina 130. Univ St Andrews, St Andrews, Fife, Scotland 131. Univ Paris, APHP, Ctr Asthme Allergies, Grp Hosp Trousseau La Roche Guyon, F-75252 Paris, France 132. Hacettepe Univ, Sch Med, Pediat Allergy Asthma Unit, Ankara, Turkey 133. George Washington Univ, Sch Med, Washington, DC USA 134. Inst Asthma Allergy, Chevy Chase, MD USA 135. Hacettepe Univ Hosp, Dept Chest Dis, Adult Allergy Unit, Ankara, Turkey 136. Charite, Inst Social Med Epidemiol Hlth Econ, D-13353 Berlin, Germany 137. McMaster Univ, Hamilton, ON, Canada 138. Hotel Dieu France, Serv Pneumol Reanimat Med, Beirut, Lebanon 139. Univ St Joseph, Fac Med, Beirut, Lebanon 140. Natl Med Ctr, Seoul, South Korea 141. Seoul Natl Univ, Seoul, South Korea 142. Korea Asthma Allergy Fdn, Seoul, South Korea 143. Ctr Hosp Univ, Serv Malad Resp, Abidjan, Cote Ivoire 144. Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Beatrix Childrens Hosp,Dept Pediat Pulmonol Ped, Groningen, Netherlands 145. Med Univ Lodz, Dept Immunol Rheumatol Allergy, Lodz, Poland 146. Karolinska Inst, Dept Clin Sci Educ, Stockholm, Sweden 147. Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden 148. Vilnius Univ, Ctr Pulmonol Allergol, Vilnius, Lithuania 149. Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania 150. Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico 151. Univ Med Pharm, Thanh Pho Ho Chi Minh, Vietnam 152. Hop Sacre Coeur Montreal, Montreal, PQ, Canada 153. Univ Montreal, Montreal, PQ, Canada 154. Guangzhou Med Coll, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China 155. Univ Tennessee, Coll Med, Memphis, TN USA 156. Univ Dundee, Ninewells Hosp, Asthma Allergy Res Grp, Dundee, Scotland 157. Dubai Hlth Author, Sharjah, U Arab Emirates 158. Univ Sharjah, Sharjah, U Arab Emirates 159. Helsinki Univ Hosp, Dept Allergy, Skin Allergy Hosp, Helsinki, Finland 160. Univ Mississippi, Med Ctr, Div Clin Immunol Allergy, Jackson, MS 39216 USA 161. Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA 162. Univ Arizona, Inst BIO5, Tucson, AZ USA 163. Shahid Beheshti Univ Med Sci, NRITLD, Tehran, Iran 164. Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Tehran, Iran 165. Charite, Dept Dermatol Allergy, D-13353 Berlin, Germany 166. Maputo Cent Hosp, Dept Peadiat, Maputo, Mozambique 167. Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique 168. Childrens Hosp La Fe, Unit Pediat Allergy Pneumol, Valencia, Spain 169. Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden 170. Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden 171. Univ Calif San Diego, Allergy Asthma Med Grp, San Diego, CA 92103 USA 172. Univ Calif San Diego, Res Ctr, San Diego, CA 92103 USA 173. IMSS, Dept Allergy Clin Immunol, Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico 174. Univ Aachen, Dept Dermatol, Aachen, Germany 175. Inst Pneumol Marius Nasta, Bucharest, Romania 176. Tishreen Univ, Sch Med, Dept Internal Med, WHO EMRO Collaborating Ctr Training Res Chron R, Latakia, Syria 177. CUF Descobertas Hosp, Immunoallergy Dept, Lisbon, Portugal 178. Univ Padua, Dept Pediat, Food Allergy Referral Ctr Veneto Reg, Padua, Italy 179. Mustapha Hosp, Algiers, Algeria 180. Sci Ctr Childrens Hlth RAMS, Moscow, Russia 181. Hosp Hospitaller Bros Buda, Budapest, Hungary 182. Charite, Allergie Ctr Charite ECARF, Dept Dermatol Venerol Allergy, D-13353 Berlin, Germany 183. German Red Cross Hosp Westend, Berlin, Germany 184. Jagiellonian Univ, Sch Med, Dept Pulmonol, Krakow, Poland 185. Kinshasa Univ, ENT Dept, Kinshasa, Zaire 186. Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan 187. Nippon Med Sch, Dept Otolaryngol, Bunkyo Ku, Tokyo 113, Japan 188. Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso 189. Marmara Univ, Div Pediat Allergy Immunol, Istanbul, Turkey 190. Mem Hlth Grp, Istanbul, Turkey 191. Charles Univ Prague, Fac Med Plzen, Dept Immunol Allergol, Prague, Czech Republic 192. MESSERLI Res Inst, Vienna, Austria 193. Med Univ Vienna, Univ Vet Med Vienna, Vienna, Austria 194. Univ Vienna, Vienna, Austria 195. Ajou Univ, Sch Med, Suwon 441749, South Korea 196. NICE, Paris, France 197. Soc Pneumol Langue Francaise, Paris, France 198. Krankenhaus Hietzing, Karl Landsteiner Inst Expt Clin Pneumol, Dept Pulm Med, Vienna, Austria 199. Alexanders Univ Hosp, Clin Allergy Asthma, Sofia, Bulgaria 200. Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulmonol, Groningen, Netherlands 201. Univ Cape Town, Lung Inst, ZA-7925 Cape Town, South Africa 202. Groote Schuur Hosp, ZA-7925 Cape Town, South Africa 203. Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands 204. Grosshansdorf Clin, Grosshansdorf, Germany 205. Hop Prive Athis Mons, Serv Pneumol, Athis Mons, France 206. Helsinki Univ Hosp, Dept Dermatol, Skin Allergy Hosp, Helsinki, Finland 207. Tech Univ Munich, CKCARE, Dept Dermatol Allergy Biederstein, Munich, Germany 208. Univ Wisconsin, Sch Med Publ Hlth, Madison, WI USA 209. Med Univ Silesia, Dept Clin Internal Dis Allergol Clin Immunol, Katowice, Poland 210. Complesso Integrato Columbus, Allergy Unit, Rome, Italy 211. IRCCS Oasi Maria SS, Troina, Italy 212. Son Pisa Primary Care Ctr, IB Salut Balear Hlth Serv, Int Primary Care Resp Grp, Palma de Mallorca, Spain 213. Hosp Luz, Immunoallergy Dept, Lisbon, Portugal 214. Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA 215. Childrens Mercy Hosp, Kansas City, MO USA 216. Emek Med Ctr, Afula, Israel 217. Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel 218. Ctr Med Docente La Trinidad, Dept Allergy Clin Immunol, Caracas, Venezuela 219. UCL, Royal Natl TNE Hosp, London, England 220. Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland 221. Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy Resp Res Grp, Edinburgh, Midlothian, Scotland 222. Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol Rheumatol, Sao Paulo, Brazil 223. Natl Ctr Cardiol Internal Med, Bishkek, Kyrgyzstan 224. Ctr ACI Immunoflow, Czech Initiat Asthma, Prague, Czech Republic 225. GAAPP, Vienna, Austria 226. Ctr Res Environm Epidemiol CREAL, Barcelona, Spain 227. Pontificia Univ Catolica RGS, Sch Med, Porto Alegre, RS, Brazil 228. Univ Nevada, Sch Med, Reno, NV 89557 USA 229. Hosp Mar, Municipal Inst Med Res IMIM, Barcelona, Spain 230. CIBER Epidemiol Salud Publ CIBERESP, Barcelona, Spain 231. Univ Pompeu Fabra UPF, Barcelona, Spain 232. Jagiellonian Univ, Coll Med, Krakow, Poland 233. Coimbra Univ Hosp, Immunoallergy Dept, Coimbra, Portugal 234. Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA 235. Finnish Inst Occupat Hlth, Helsinki, Finland 236. Univ Laval, Fac Med, Dept Obstet Gynecol, Laval, PQ, Canada 237. Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol Allergy Res,Ctr Pathophysiol, Vienna, Austria 238. Hosp Clin Barcelona, Dept Pneumol, Allergy Unit, Immunoallergia Resp Clin, Barcelona, Spain 239. IDIBAPS, Barcelona, Spain 240. CIBERES, Barcelona, Spain 241. Univ Paris 13, Bobigny, France 242. Avicenne Hosp, AP HP, Bobigny, France 243. Vilnius Univ, Fac Med, Dept Paediat, Vilnius, Lithuania 244. Lithuanian Natl Council Childs Hlth, Vilnius, Lithuania 245. Terveystalo Turku, Allergy Clin, Turku, Finland 246. Univ Turku, Dept Lung Dis Clin Immunol, Turku, Finland 247. Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium 248. Catholic Univ Louvain, Univ Hosp Mt Godinne, Yvoir, Belgium 249. Radboud Univ Nijmegen, Med Ctr, Dept Primary Community Care, NL-6525 ED Nijmegen, Netherlands 250. Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand 251. CNR, IBIM, Palermo, Italy 252. Clin Physiol IFC, Pisa, Italy 253. Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore 254. Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden 255. Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden 256. Floridsdorf Allergy Ctr FAZ, Vienna, Austria 257. Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria 258. Bradford Teaching Hosp Fdn Trust, Bradford Inst Hlth Res, Bradford, W Yorkshire, England 259. Olmsted Med Ctr, Dept Res, Rochester, MN USA 260. Univ Minnesota, Dept Family Community Hlth, Rochester, MN USA 261. Harvard Univ, Sch Publ Hlth, Cyprus Int Inst Environm Publ Hlth Assoc, Limassol, Cyprus 262. Cyprus Univ Technol, Limassol, Cyprus 263. Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat Child Hlth, ZA-7925 Cape Town, South Africa 264. Catholic Univ Cordoba, Sch Med, Dept Otorhinolaryngol, Cordoba, Argentina 265. Guangzhou Med Coll, Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China 266. Guangzhou Med Coll, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China 267. Univ Clin Resp Allerg Dis, Golnik, Slovenia 268. Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany 269. Charite, Network Excellence, Global Allergy Asthma European Network GA2LEN, D-13353 Berlin, Germany 基金资助机构 授权号 Stallergenes ALK-Abello European Academy of Allergy and Clinical Immunology (EAACI) MSD Novartis Nycomed/Takeda PHADIA/Thermo Fischer 3M AstraZeneca GlaxoSmithKline Merck Frosst Altair Amgen Asmacure Boehringer-Ingelheim Genentech Pharmaxis Schering Wyeth Ache Brazilian Research Council Fundacao de Amparo a Pesquisa da Bahia Fundacao Ciencia e Tecnologia Sociedade Portuguesa de Alergologia e Immunologia Clinica Abdi Ibrahim OrionPharma Nasonebs Merck McNeal Chiesi Nycomed Air Liquid Healthcare Mundipharma Almirall Kyorin Teva UK National Health Service Aerocrine AKL Ltd PREDICTA Swiss National Science Foundation MeDALL Global Allergy and Asthma European Network (GA 2LEN) Christine Kuthe Center for Allergy Research and Education Faes Farma Bial Johnson Johnson Sanofi HAD treasurer Innovative Medicine Initiative (EU) Helse Sor-Ost RHF (Southern and Eastern Norway Regional Health Authority) MEDA Alcon ISTA Thermo-Fisher Airsonett Medical Research Council Moulton Charitable Trust AB Science Canadian Institutes for Health Research AllerGen NCE Merck/Schering-Plough Circassia University Hospital Medical School of Universidad Autonoma de Nuevo Leon, Mexico Children's Research Foundation (Ireland) Danone Food Standards Agency (United Kingdom) European Union (EU) DTG Netherlands Asthma Foundation Merck-Sharp-Dohme, Mexico Allerquim Mexico Abbott Apotex HRA MedImmune Schering-Plough Proctor Gamble Sunovion (Sepracor) Phadia Servier CSC JohnsonJohnson Oxygen Plus New Medics European Respiratory Society Societe de Pneumologie de Langue Francaise Asthma Ministry of Health, Welfare, and Labor Altana Takeda UCB Uriach advisory board NAPP Royal College of GPs Clinical Champion in Allergy Agency for Healthcare Research and Quality (AHRQ) AnseII Bayer Schering OST Fujisawa IHAL Henkel Kryolan Leti MSO Procter and Gamble Sanofi-Aventis Scientific Advisory Board for the German Society for Allergy and Clinical Immunology German Federal Ministry of Consumer Protection European Centre for Allergy Research Foundation (ECARF)
之前一篇博文 《 中国审稿人怎么了？竟然把评审的稿件拒了后，换上自己的名字重投 》引起很高的关注度，大家都在唾弃这种令人发指的行为。可是，在各种投来的稿件中，出现各种学术不端并不稀奇（总有想走捷径的人），那编辑们发现了这样的论文该如何处理呢？ 1.悄悄的退稿，声张的不要； 2.1.退稿，在期刊主页上放上声明（这次的事件。《电子学报》好像选的就是这种方法）； 2.2.退稿并把情况反映给作者所在的院校； 3.退稿，通报给作者学校，并在期刊首页放上声明； 4.退稿，通报作者学校，在期刊首页放上声明，同时通报给同领域的其他期刊。 以上，几种方式严厉程度在增加。显然，最后一种方式的威力是毁灭性的，基本就会结束一个人的学术生涯了。但是，前面的做法又威慑力有点小。不知道各位更赞成那种方式？ 个人更倾向于4，自己要为自己的行为负责嘛。 PS：附上之前看过的一个 编辑对一稿多投的处理意见 ，很有震慑力呀（株连九族了 ）： I am disappointed to find that this is a duplicate submission. You also submitted this paper to the XXXXXXXXXX. Duplicate submissions are not allowed, thus your paper is immediately rejected. XXXXX As a result of this flagrant violation of standard international rules of scholarship, XXXXXX has no choice but to reject your paper. In addition, XXXXXX will not accept future submissions from you or any of your colleagues, I will forward this message to your Dean, and I am passing this situation on to other journal editors in our field. This is a grave disappointment. Honesty and integrity are essential to science and this kind of action brings shame on you and your university.
讲一个实验室的故事，故事总共涉及到 8 个人，暂且称他们： A 、 B 、 C 、 D 、 E 、 F 、 G 、 H 。其中： A 是实验室的 PI ，还是 C 的 Supervisor 。 B 是法国的访问学生，他最先做这个课题，做了 3 个月就走人了。其间他摸索出了一些方法，获得了一些不完整的数据，然后交给了 C 。 C 是 A 的博士生， B 走了之后， A 让 C 继续做 B 的工作。 C 在 B 的基础上，用了 5 个月时间，优化了实验方法，获得了一些比较理想的数据（但没有用到 B 的数据），写了文章然后投了出去，结果是大修改，补做实验后需要重投。这时候访问学生 D 来了 , 于是 A 把任务又交给了学生 D ， C 被转到了 A 布置的其他任务。 D 是荷兰的访问学生， D 又在 C 的基础上，用了 6 个月时间，继续优化实验条件，获得了比较系统的数据（也没有用到 B 、 C 的数据），写了文章投了出去，最终文章被接收了。 E 是 D 在荷兰的 Supervisor 。 F 是 G 和 H 的上司，他指示 G 、 H 协助试验，并参与了试验结果的分析讨论。 G 和 H 都是 F 的 research assistant, G 负责材料的一项定性测试， H 在初期教 B 、 C 、 D 怎么使用仪器。 G 和 H 都未参与文章的成稿。 被接收的文章，究竟怎么署名才算合理呢？ 发表文章的实际署名顺序是： A 、 D 、 F 、 G 、 H 、 E ，其中 A 既是第一作者又是通讯作者。 B 、 C 虽然为 D 进行了大量实验方法和条件的探索 ，但也最终也只是牺牲品，连成为作者的资格都没有。（实际上他们应该成为作者吗？） E 完全是搭便车，挂个名而已，主要是 A 为了加深与他的关系。 据了解，现实中很多文章的署名都不科学，甚至包括 很多所谓的“牛人”。不少导师为了结盟（加强与同行的联系），似乎总喜欢加些与项目不相干人的名字。这样的“抱团”结果，表面上是多赢：学生、导师和第三方的同行，每个人都多了一篇文章，还加强了彼此之间的“合作”，背后却污染了科学的空气。也许这就是，当前除了第一作者和通讯作者，其他作者越来越不被看重的部分原因。 作者在署名时，有时候也比较困惑，署名少了，别人认为你没有合作精神；署名多了，一些不该构成作者的人也成了作者。目前， 少数杂志要求明确所有作者贡献的做法，其实还是很值得倡导和推广的 。
Andrew Fire 和 Craig Mello因发现双链RNA引发基因沉默现象而获Nobel奖。 评奖委员会认为突破性的进展发表于1998年nature上的一篇文章。 在这篇文章中，Andrew FIre是第一作者和通讯作者，而Craig Mello是最后一个作者。其余作者与诺奖无缘。 据我所知，通讯作者并不是中国人发明的。许多著名杂志明确定义了corresponding author的责任。 PNAS《美国科学院院刊》 We have codified a change in our interpretation of corresponding author. This term means literally the person who handles correspondence regarding a paper, but by implication and practice, it also identifies a guarantor of the published work. We now state explicitly that the corresponding author must be a guarantor of a significant part or all of the work. A coauthor can also be a guarantor as indicated in the opening statement of principles. 参见：http://www.pnas.org/content/101/29/10495.full Nature ----- Corresponding author - prepublication responsibilities The corresponding (submitting) author is solely responsible for communicating with the journal and with managing communication between coauthors. Before submission, the corresponding author ensures that all authors are included in the author list, its order has been agreed by all authors, and that all authors are aware that the paper was submitted. After acceptance, the proof issent to the corresponding author, who circulates it to all coauthors and deals with the journal on their behalf; the journal will not necessarily correct errors after publication if they result from errors that were present on a proof that was not shown to coauthors before publication. The corresponding author is responsible for the accuracy of all content in the proof, in particular that names of coauthors are present and correctly spelled, and that addresses and affiliations are current. Corresp onding author - responsibilities after publication The journal regards the corresponding author as the point of contact for queries about the published paper. It is this author's responsibility to inform all coauthors of matters arising and to ensure such matters are dealt with promptly. This author does not have to be the senior author of the paper or the author who actually supplies materials; this author's role is to ensure enquiries are answered promptly on behalf of all the co-authors . The name and e-mail address of this author (on large collaborations there may be two) is published in the paper. 参见：http://www.nature.com/authors/editorial_policies/authorship.html ----------- 中国的学术评价体系给通讯作者附加另一层含义，即责任作者。有些类似于PNAS中的定义，即为论文数据的真实性承担责任，同时较多地享有此论文可能获得的荣誉。 另外，在欧美体系的生物学杂志中，往往认为senior author排在最后。我想这可能是Craig Mello作为最后一名作者，可以与Andrew Fire共享Nobel奖的原因吧。
文章题目： Observation and properties of the X(3872) decaying to J/psipi(+)pi(-) in pp collisions at sqrt =1.96 TeV. 文章地址：http://www.ncbi.nlm.nih.gov/pubmed/15524981 影响力：2004年发表，至今引用6次，google学术搜素
还没有来得及仔细研究，觉得有些用处，与大家共享。 http://www.authormapper.com AuthorMapper searches journal articles and plots the location of the authors on a map. 以下内容来源于图书馆介绍： Springer近期推出了AuthorMapper服务AuthorMapper网站提供浏览模式的搜寻，亦可以用关键词来搜寻，还可以取得各种相关的统计资料利用Google Map来呈现，该数据库目前已经有三百万篇期刊学术论文，透过这个服务使用者可以很方便了解一个学术领域或议题，在各国/各研究机构之间的论文发表数量的比较。
对浙大院士课题组的论文事件已有众多评论，因为事不关己，只浏览了少数的评论。此前曾目睹过前老板被同事指控在投稿时随意删除或添加作者，因而得知审理这类案件国外机构会引用温哥华议定书（Vancouver Protocol, www.icmje.org）。 议定书明确了要被列为作者以下三条必须全部满足： 1. 对构思和设计，获取数据，或分析解释数据有显著贡献， 2.起草文章或修改文章重要的学术内容， 3.参与定稿。 （Authorship credit should be based on 1） substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2） drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.） 议定书并明确指出仅仅参与获取科研资金，或收集数据，或作常规的监管不足以被列为作者。 对照温哥华议定书，显然浙大院士和实验室主任的行为完全越轨了。浙大既然宣称要角逐世界一流，那么就必须要顺应国际惯例。如果浙大尚未有明确的科研守则，何不应尽快参照其他大学的守则写出草案，公示后成为正式文件向师生传达? 处理这起院士课题组的论文事件既棘手而又不讨好，那么为什么不防患于未然？与其给学生开爱国课，倒不如向师生介绍科研伦理，不出丑闻不给中国丢脸，不就是爱国吗？！ 再贴一段澳洲著名免疫学家Gustav Nossal 回忆诺贝尔奖得主Macfarlane Burnet时的讲话：One of the minor regrets, not really a big regret, is that Ive never published a paper with Mac Burnet. Ive published 500 papers, not a single one has Burnet as a co-author. He did not believe in putting his name on a paper if he hadnt done at least one third of the work himself. A sort of an honest unselfish approach, when it comes time to reap the glory you do it without having someone grabbing it instead of you. Macfarlane Burnet只有在自己对文章有三分之一以上贡献时才肯把自己列为作者 --- 这才是真正的大师！
标签: 作者
![[转载]掷硬币决定署名顺序](http://image.sciencenet.cn/album/201206/14/12584696jibuuuzui9yiu2.jpg.thumb.jpg)
